+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation



Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation



Movement Disorders 17(5): 887-901



Piribedil ([1-(3,4-methylenedioxybenzyl)-4-(2-pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D(2)/D(3) dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L-dopa). However, its ability to prime basal ganglia for the appearance of dyskinesia is unknown. We now report on the ability of repeated administration of piribedil to induce dyskinesia in drug naïve 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -lesioned common marmosets compared with L-dopa and its actions on the direct and indirect striatal outflow pathways. Administration of piribedil (4.0-5.0 mg/kg orally) or L-dopa (12.5 mg/kg orally plus carbidopa 12.5 mg/kg orally twice daily) produced equivalent increases in locomotor activity and reversal of motor deficits over a 28-day study period. Administration of L-dopa resulted in the progressive development of marked dyskinesia over the period of study. In contrast, administration of piribedil produced a significantly lower degree and intensity of dyskinesia. Surprisingly, piribedil caused an increase in vigilance and alertness compared to L-dopa, which may relate to the recently discovered alpha(2)-noradrenergic antagonist properties of piribedil. The behavioural differences between piribedil and L-dopa are reflected in the biochemical changes associated with the direct striatal output pathway. Administration of L-dopa or piribedil did not reverse the MPTP-induced up-regulation of preproenkephalin A mRNA in rostral or caudal areas of the putamen or caudate nucleus. In contrast, administration of either piribedil or L-dopa reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. L-dopa, but not Piribedil, reversed the decrease in preproenkephalin B mRNA produced by MPTP treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047236265

Download citation: RISBibTeXText

PMID: 12360537

DOI: 10.1002/mds.10200


Related references

Piribedil induces low levels of dyskinesia in MPTP-treated common marmosets. Neurology 54(7 Supp 3): A53, 2000

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115(4): 1047-1058, 16 December, 2002

Effects of repeated treatment with combinations of L-DOPA and ropinirole on dyskinesia induction in MPTP-treated common marmosets. British Journal of Pharmacology 123(PROC Suppl. ): 252P, 1998

Inducing dyskinesia in MPTP-treated common marmosets The effects of repeated treatment with combinations of L-dopa and ropinirole. Neurology 50(4 Suppl. 4): A135, 1998

Comparison of repeated treatment with L-DOPA, pergolide and apomorphine on dyskinesia induction in MPTP-treated common marmosets. British Journal of Pharmacology 125(PROC Suppl. ): 4P, 1998

Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. Experimental Neurology 221(1): 79-85, 2010

The ability of ropinirole to reverse L-dopa-induces dyskinesia in MPTP-treated marmosets. European Journal of Neurology 10(Suppl. 1): 19, 2003

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. European Journal of Neuroscience 13(3): 597-608, 2001

A comparison of ropinirole, L-dopa, and bromocriptine treatment on the development of dyskinesia in MPTP-treated common marmosets. Neurology 48(3 Suppl. 2): A119, 1997

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental Neurology 204(1): 162-170, 2007

Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology 142(1): 51-60, 1999

Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Journal of Neural Transmission 121(2): 163-169, 2014